Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Sepsis, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADM drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ADM Recombinant Protein / Peptide High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View ADM Products |
| Gene Delivery | ADM Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View ADM Products |
| Benchmark Ab | Anti-ADM (Sequence of Adrecizumab) Recombinant positive control. |
View ADM Products |
| Validator | ADM siRNA Set For knockdown verification. |
View ADM Products |
| Related Target A | CALCRL Core GPCR component of the Adrenomedullin receptor complex. |
View CALCRL Products |
| Related Target B | RAMP2 Receptor activity-modifying protein crucial for ADM specificity. |
View RAMP2 Products |
| Related Target C | ADM2 (Intermedin) Peptide homolog essential for paralog selectivity assays and off-target counter-screening. |
View ADM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ADM ortholog proteins available with >95% purity; Sequence Verified. |
| Complex Receptor Assays (GPCR + RAMP) | Lentivirus Premade Particles for stable CALCRL/RAMP2 co-expression; cell-based assays preserve native conformation. |
| Rapid Peptide Degradation / Instability | Sequence-verified, highly stable recombinant ADM variants with theoretical MW precision. |
| Homolog selectivity (ADM vs ADM2/Intermedin) | Homolog panel proteins strictly verified by mass spec for clean counter-screening. |
| Lack of Controls for N-terminal binding | Clinical Benchmark Antibodies (Adrecizumab Biosimilar) included as recombinant positive controls. |
| False Positives / Specificity | Validated siRNA included for specificity checks. |
Live ADM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Adrenomedullin (ADM) therapeutics is intensifying, with major players shifting focus from traditional antagonists to non-neutralizing monoclonal antibodies and peptide mimetics. As first-generation therapies reach the clinic—particularly for sepsis and cardiogenic shock—the next wave of R&D is targeting chronic heart failure, inflammatory bowel disease (IBD), and tumor microenvironment modulation. Targeting ADM requires a nuanced approach, as preserving its beneficial endothelial barrier-stabilizing effects while mitigating pathological systemic vasodilation is paramount.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Non-neutralizing mAb | Adrenomed, MAB Discovery | Sepsis, Septic Shock | Epitope Mapping (Need high-purity N-terminal ADM fragments) |
| Peptide Agonist | Eiger BioPharmaceuticals | Pulmonary Arterial Hypertension | Cell-based Calcium Flux (Need Lentivirus for CALCRL/RAMP2) |
| Small Mol Antagonist | Various Academic / Preclinical | Solid Tumors (Angiogenesis) | Selectivity Assay (Need strict GPCR counter-screening panels) |